These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 16848644)

  • 21. Hydro-alcoholic extract of Crocus sativus L. versus fluoxetine in the treatment of mild to moderate depression: a double-blind, randomized pilot trial.
    Noorbala AA; Akhondzadeh S; Tahmacebi-Pour N; Jamshidi AH
    J Ethnopharmacol; 2005 Feb; 97(2):281-4. PubMed ID: 15707766
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is anxious-agitated major depression responsive to fluoxetine? A double-blind comparison with amitriptyline.
    Marchesi C; Ceccherininelli A; Rossi A; Maggini C
    Pharmacopsychiatry; 1998 Nov; 31(6):216-21. PubMed ID: 9930635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials.
    McGirr A; Vöhringer PA; Ghaemi SN; Lam RW; Yatham LN
    Lancet Psychiatry; 2016 Dec; 3(12):1138-1146. PubMed ID: 28100425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is metabolic dysregulation associated with antidepressant response in depressed women in climacteric treated with individualized homeopathic medicines or fluoxetine? The HOMDEP-MENOP Study.
    Macías-Cortés ED; Llanes-González L; Aguilar-Faisal L; Asbun-Bojalil J
    Homeopathy; 2017 Feb; 106(1):3-10. PubMed ID: 28325221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians.
    Qaseem A; Snow V; Denberg TD; Forciea MA; Owens DK;
    Ann Intern Med; 2008 Nov; 149(10):725-33. PubMed ID: 19017591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Moclobemide versus fluoxetine in the treatment of major depressive disorder in adults.
    Lapierre YD; Joffe R; McKenna K; Bland R; Kennedy S; Ingram P; Reesal R; Rickhi BG; Beauclair L; Chouinard G; Annable L
    J Psychiatry Neurosci; 1997 Mar; 22(2):118-26. PubMed ID: 9074306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amitriptyline versus placebo for major depressive disorder.
    Leucht C; Huhn M; Leucht S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009138. PubMed ID: 23235671
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial.
    Gillin JC; Rapaport M; Erman MK; Winokur A; Albala BJ
    J Clin Psychiatry; 1997 May; 58(5):185-92. PubMed ID: 9184611
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram].
    Favré P
    Encephale; 2012 Feb; 38(1):86-96. PubMed ID: 22381728
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials.
    Tedeschini E; Levkovitz Y; Iovieno N; Ameral VE; Nelson JC; Papakostas GI
    J Clin Psychiatry; 2011 Dec; 72(12):1660-8. PubMed ID: 22244025
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluoxetine and concomitant centrally acting medication use during clinical trials of depression: the absence of an effect related to agitation and suicidal behavior.
    Wernicke JF; Sayler ME; Koke SC; Pearson DK; Tollefson GD
    Depress Anxiety; 1997; 6(1):31-9. PubMed ID: 9394873
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Comparative efficacy and acceptability of new-generation antidepressants. Synthesis meta-analysis Cipriani].
    Gaillard R
    Encephale; 2009 Oct; 35(5):499-504. PubMed ID: 19853726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug dose as mediator of treatment effect in antidepressant drug trials: the case of fluoxetine.
    Purgato M; Gastaldon C; Papola D; Magni LR; Rossi G; Barbui C
    Acta Psychiatr Scand; 2015 Jun; 131(6):408-16. PubMed ID: 25495269
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of fluoxetine for anorexia nervosa caused by chemotherapy in patients with cholangiocarcinoma.
    Guo LQ; Sun HW; Zhang CY; Feng Y; Teng XL; Qu YK
    Medicine (Baltimore); 2019 Jun; 98(24):e15945. PubMed ID: 31192931
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bootstrap methods for adaptive designs.
    Rosenberger WF; Hu F
    Stat Med; 1999 Jul; 18(14):1757-67. PubMed ID: 10407246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Precision and comparability of adverse event rates of newer antidepressants.
    Vida S; Looper K
    J Clin Psychopharmacol; 1999 Oct; 19(5):416-26. PubMed ID: 10505583
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic inadequacy in spite of bioequivalency on replacing Fluctine with Fluocim.
    Albrecht J; Adler RH
    Swiss Med Wkly; 2001 Feb; 131(5-6):84. PubMed ID: 11383231
    [No Abstract]   [Full Text] [Related]  

  • 38. Response to "Antidepressants and cancer: cause for concern?".
    Pande AC
    J Clin Psychopharmacol; 1993 Dec; 13(6):458. PubMed ID: 8120165
    [No Abstract]   [Full Text] [Related]  

  • 39. Fluoxetine in stroke (FOCUS) trial-reasons to be cheerful about antidepressants in stroke?
    Quinn TJ
    Ann Transl Med; 2019 Jul; 7(Suppl 3):S131. PubMed ID: 31576338
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.